Thalia Therapeutics PLC (THAT)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.40p

Buy

0.50p

arrow-up0.025p (+5.88%)

Prices updated at 02 Apr 2026, 14:21 BST

Prices minimum 15 mins delay

Prices in GBX

N4 Pharma PLC is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. Its vaccines include Nuvac and Nuvec.

FTSE All-Share

0.59%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Christopher Jonathan Britten

CEO

-

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

4

Head office

C/o Arch Law Limited

London

United Kingdom

EC2N 4BQ

-

info@n4pharma.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Christopher Jonathan Britten Non-Executive Director, Chairman	-
Dr. Michael G. Palfreyman Non-Executive Director	-
Dr. David Alastair Maclaughlin Smith Non-Executive Director	-
Mr. Edward Wardle Non-Executive Director	-
Mr. Luke Sebastian Cairns Executive Director	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
No data

Director dealings

Date chevron-l-regular chevron-r-regular	Action
04 Apr 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.